ALLMedicine™ Cholangiocarcinoma Center

Jan 26th, 2023 - Standard approach to address common bile duct stones is endoscopic retrograde cholangiography (ERC) with sphincterotomy. Those interventions are performed either before or after gallbladder removal (cholecystectomy), thus, requiring at least two i...

Jan 26th, 2023 - Background: Cholangiocarcinoma (CCA) is an aggressive biliary tract malignancy that remains a clinical challenge with limited treatment options and poor survival. Combination chemotherapy with gemcitabine and cisplatin is the most validated first-...

Jan 25th, 2023 - Clonorchis sinensis is an important food-borne zoonotic parasite which has been linked to biliary fibrosis and cholangiocarcinoma. However, the details of the pathogenesis of C. sinensis were unclear. To explore the role and regulatory mechanism o...

Jan 25th, 2023 - The ACTICCA-1 investigator initiated trial is funded by the Deutsche Krebshilfe (grant number 70110215, 70112047). With respect to data obtained in the ABC-02 trial, the combination of cisplatin and gemcitabine for 24 weeks as investigational trea...

Jan 25th, 2023 - Background: Primary liver cancer (PLC) is the 2nd most common cause of cancer-related death worldwide and the one cancer with the fastest rising incidence and mortality in the U.S. PLC consists of two main histological subtypes, i.e., hepatocellul...

Oct 25th, 2021 - This guideline provides evidence-based recommendations for the indications and technique-dose of external beam radiation therapy (EBRT) in hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC). The American Society for Radiation...

May 25th, 2021 - The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging, treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and cancer of the bile ducts (intrahepatic and extrahepatic cholangiocarcino...

Dec 2nd, 2020 - The Japanese Society of Hepato-Biliary-Pancreatic Surgery launched the clinical practice guidelines for the management of biliary tract cancers (cholangiocarcinoma, gallbladder cancer, and ampullary cancer) in 2007, then published the 2nd version ...

Jul 16th, 2019 - The purpose of this clinical practice update is to define key principles in the surveillance of hepatobiliary cancers including cholangiocarcinoma, gallbladder adenocarcinoma, and hepatocellular carcinoma in patients with primary sclerosing cholan...

Mar 12th, 2019 - To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with resected biliary tract cancer. ASCO convened an Expert Panel to conduct a systematic review of the literature on adjuvant therapy for ...

Jan 26th, 2023 - Background: Cholangiocarcinoma (CCA) is an aggressive biliary tract malignancy that remains a clinical challenge with limited treatment options and poor survival. Combination chemotherapy with gemcitabine and cisplatin is the most validated first-...

Jan 26th, 2023 - Standard approach to address common bile duct stones is endoscopic retrograde cholangiography (ERC) with sphincterotomy. Those interventions are performed either before or after gallbladder removal (cholecystectomy), thus, requiring at least two i...

Jan 25th, 2023 - Background: Among the new cases of bile tract carcinoma (BTC) that are diagnosed every year in the United States, there are approximately 6,500 cases of gallbladder carcinoma, 3,000 cases of extrahepatic cholangiocarcinoma, and 3,000 cases of intr...

Jan 25th, 2023 - This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 as a single agent and in combination with other anti-cancer drugs in patients with advanced solid tumors and gliomas. The study is divided into two parts: single agent ...

Jan 25th, 2023 - The ACTICCA-1 investigator initiated trial is funded by the Deutsche Krebshilfe (grant number 70110215, 70112047). With respect to data obtained in the ABC-02 trial, the combination of cisplatin and gemcitabine for 24 weeks as investigational trea...

Jan 4th, 2023 - An investigation of genomics data related to primary sclerosing cholangitis (PSC) in published medical literature revealed several genes likely involved in the pathogenesis of this autoimmune diseases, according to a study published in Gastro Hep.

Nov 23rd, 2022 - RLY-4008, a highly selective FGFR2 inhibitor, has demonstrated promising efficacy in patients with FGFR2-altered cholangiocarcinoma, while sparing patients the adverse effects (AEs) typically seen with pan-FGFR inhibitors, according to Suneel Kama...

Nov 21st, 2022 - Molecular and immune landscapes for solid tumors are constantly evolving as precision medicine techniques become more sensitive and next-generation sequencing methods (NGS) are taken up in clinical practice. Posters presented at the European Soc...

Nov 12th, 2022 - Untreated chronic hepatitis B infections are associated with increased risks of most major extrahepatic cancer types, shows a new study conducted in South Korea. In this study, which was published in the Journal of Clinical Oncology, researchers f...

Nov 10th, 2022 - With a treatment paradigm that is burgeoning with research as well as unanswered questions, neuroendocrine neoplasm experts are focused on determining optimal treatment sequences and improving quality of life (QOL) for both poorly differentiated a...